Evoke Pharma to Report Fourth Quarter and Full Year 2022 Results on March 21, 2023
March 15, 2023 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma and EVERSANA Selected to Present Results of Real-World Healthcare Utilization Study Comparing GIMOTI® and Oral Metoclopramide at the Digestive Disease Week Plenary Session
February 21, 2023 07:00 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Announces Teva Ends Pursuit of Paragraph IV ANDA Against Gimoti
January 30, 2023 07:00 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma Announces Acceptance of an Abstract at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2023
January 18, 2023 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
USPTO Grants New Patent to Evoke Pharma Covering the Usage of GIMOTI® To Treat Moderate to Severe Gastroparesis
December 07, 2022 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma Strengthens its Intellectual Property Portfolio with a Notice of Allowance from the USPTO for a Patent Application Related to GIMOTI®
November 30, 2022 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma Reports Record Third Quarter 2022 Financial Results
November 09, 2022 16:05 ET
|
Evoke Pharma, Inc.
80% increase in GIMOTI® net revenue over Q2 202256% increase of GIMOTI prescription fills in Q3 compared to Q213% increase of new prescribers of GIMOTI over Q2 SOLANA BEACH, Calif., Nov. 09, 2022 ...
Evoke Pharma to Report Third Quarter Results on November 9, 2022
November 02, 2022 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today...
Evoke Pharma to Participate in the 2022 American College of Gastroenterology Annual Scientific Meeting
October 20, 2022 08:44 ET
|
Evoke Pharma, Inc.
Company will exhibit Gimoti® and meet with Key Opinion Leaders Healio Industry Breakthrough Product Award Nominee SOLANA BEACH, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma,...
Evoke Pharma Receives Notice of Allowance from USPTO for a Patent Related to GIMOTI
September 20, 2022 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...